Crisis Leadership Custom Case Solution & Analysis

1. Evidence Brief: Crisis Leadership Case Study

Financial Metrics

Market Share: Tylenol held 35 percent of the over the counter analgesic market prior to the crisis.
Recall Cost: The projected financial impact of a national recall was approximately 100 million dollars after tax.
Product Volume: 31 million bottles of Tylenol were in circulation at the time of the incident.
Revenue Contribution: Tylenol accounted for 7 percent of Johnson and Johnson total sales but contributed 17 percent of its net income.

Operational Facts

Event: Seven deaths occurred in the Chicago area due to cyanide laced Extra Strength Tylenol capsules.
Packaging: The product featured no tamper resistant seals; capsules were easily opened and resealed.
Distribution: The product was distributed through thousands of retail outlets across the United States.
Manufacturing: Internal testing confirmed that cyanide contamination did not occur at the manufacturing plants in Pennsylvania or Texas.

Stakeholder Positions

James Burke (CEO): Positioned the Johnson and Johnson Credo as the primary decision making filter. Advocated for total transparency with the public.
Lawrence Foster (VP of Public Relations): Focused on maintaining open channels with the media to prevent panic.
The FBI and FDA: Advised against a national recall to avoid rewarding the perpetrator and causing unnecessary public alarm.
Consumers: Expressed high levels of fear; initial surveys indicated 90 percent of consumers would not buy the product again.

Information Gaps

Perpetrator Identity: The identity and motive of the individual responsible for the tampering remained unknown during the decision window.
Legal Liability: The case does not specify the projected cost of litigation or potential settlements for the seven deaths.
Competitor Response: Detailed data on how competitors like Bristol Myers or American Home Products planned to capture the 35 percent market vacancy was absent.

2. Strategic Analysis

Core Strategic Question

How can Johnson and Johnson preserve its long term corporate reputation and the Tylenol brand while managing an immediate public health crisis and a 100 million dollar financial loss?

Structural Analysis

The Johnson and Johnson Credo serves as the primary strategic framework. It establishes a hierarchy of responsibility: consumers first, employees second, communities third, and stockholders last. This hierarchy simplifies the decision process during a crisis by removing the conflict between profit and safety. From a Brand Equity perspective, the Tylenol name is the most valuable intangible asset. If the brand loses trust, the asset value drops to zero. Protecting the brand requires a radical commitment to consumer safety that exceeds regulatory requirements.

Strategic Options

Option	Rationale	Trade-offs	Resource Requirements
Regional Recall (Chicago Only)	Limits financial loss and follows FBI/FDA advice to minimize panic.	Risk of deaths in other regions; looks like profit seeking over safety.	Minimal logistics; localized PR team.
National Recall and Relaunch	Eliminates all risk to consumers and demonstrates total commitment to the Credo.	100 million dollar cost; potential permanent loss of market share.	Massive logistics for 31 million bottles; R&D for new packaging.
Product Discontinuation	Ends the liability immediately and protects the parent company brand.	Cedes 35 percent market share to competitors; admits defeat.	Write down of all Tylenol related assets.

Preliminary Recommendation

Execute a national recall of all Tylenol capsules immediately. While the FBI and FDA suggest a localized approach, the risk of a single death outside Chicago would permanently destroy the Johnson and Johnson brand. The Credo dictates that the consumer comes first. By prioritizing safety over the 100 million dollar hit, the company earns the moral authority to relaunch the product with tamper resistant packaging.

3. Implementation Roadmap

Critical Path

Immediate Stop: Cease all production and advertising of Tylenol capsules within 24 hours.
Public Notification: Issue a national alert advising consumers to stop using Tylenol capsules until further notice.
Reverse Logistics: Establish a collection system for 31 million bottles through retailers and a consumer exchange program for tablets.
Product Redesign: Accelerate the development of triple seal tamper resistant packaging.
Relaunch: Reintroduce the product with a massive discount program to incentivize consumer return.

Key Constraints

Logistical Friction: Moving 31 million units from retail shelves to disposal sites requires a massive coordination of the supply chain that the company does not fully control.
Media Saturation: The story is a national sensation. Any inconsistency in communication will be amplified and interpreted as a cover up.
Packaging Technology: Triple seal technology must be developed and scaled at a speed never before seen in the pharmaceutical industry.

Risk-Adjusted Implementation Strategy

The implementation must assume that the perpetrator may strike again. Therefore, the relaunch cannot simply be a return to the status quo. The contingency plan involves a permanent shift from capsules to caplets, which are harder to adulterate. The company must also establish a 24 hour crisis hotline to manage consumer anxiety directly, bypassing the filter of news media. Execution success depends on the speed of the packaging transition; every week the product is off the shelf, the brand loses 1 percent of its terminal market share.

4. Executive Review and BLUF

BLUF

Johnson and Johnson must recall all Tylenol capsules nationally. The 100 million dollar cost is significant but secondary to the survival of the 500 million dollar Tylenol franchise and the parent company reputation. Following the Credo is not just a moral choice but a pragmatic survival strategy. By taking full responsibility for a problem they did not cause, the company will secure consumer loyalty for decades. Speed and transparency are the only variables that matter. Any attempt to minimize the recall will be viewed as a prioritization of profit over human life.

Dangerous Assumption

The analysis assumes that the tampering was an isolated external event. If the investigation later reveals internal manufacturing failures or employee sabotage, the strategy of total transparency will backfire and increase legal exposure exponentially.

Unaddressed Risks

Copycat Actors: A national recall provides a blueprint for other criminals to extort the company or its competitors by contaminating products in other categories.
Financial Covenant Breaches: A 100 million dollar write down may trigger technical defaults in debt agreements or lead to a credit rating downgrade, increasing the cost of capital for future R&D.

Unconsidered Alternative

The team did not consider a strategic pivot to a prescription only model for Tylenol during the transition period. This would have maintained the brand presence in the medical community while completely removing the risk of retail tampering during the packaging redesign phase.